新型广谱四环素类抗生素依拉环素的研究  

Study on Eravacycline a Novel Totally Synthetic Broad-spectrum and Fluorotetracycline Antibiotic

作　　者：马兴换 Ma Xing-huan(The Third People’s Hospital of Weishan County,Weishan Shandong 277600)

机构地区：[1]微山县第三人民医院,山东微山277600

出　　处：《国外医药(抗生素分册)》2025年第1期39-44,共6页World Notes on Antibiotics

摘　　要：依拉环素是一种新型、全合成、广谱和含氟四环素类抗菌药物,用于治疗常见的革兰阴性菌和革兰阳性菌感染在内的多重耐药菌感染。本文主要对依拉环素构效关系、作用机制、抗菌谱、药效/药代动力学和不良反应进行概述,旨在为依拉环素的临床应用提供参考。Eravacycline is a brand-new,entirely synthetic,fluorotetracycline,broad-spectrum antibiotic that is used in China to treat common gram-positive and gram-negative bacterial infections as well as multidrug-resistant bacterial illnesses.In order to provide a reference for the clinical application,structure-activity relationship,action mechanism,pharmacokinetics,and pharmacodynamics,adverse reactions of Eravacycline are mainly described,in this article.

关 键 词：依拉环素 四环素 耐药性 核糖体 构效关系 药效药代动力学 

分 类 号：R978[医药卫生—药品]